184 related articles for article (PubMed ID: 20215522)
1. Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer.
Ahsan A; Hiniker SM; Ramanand SG; Nyati S; Hegde A; Helman A; Menawat R; Bhojani MS; Lawrence TS; Nyati MK
Cancer Res; 2010 Apr; 70(7):2862-9. PubMed ID: 20215522
[TBL] [Abstract][Full Text] [Related]
2. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
3. Co-treatment of wild-type EGFR head and neck cancer cell lines with afatinib and cisplatin.
Brands RC; Müller-Richter UD; De Donno F; Seher A; Mutzbauer G; Linz C; Kübler AC; Hartmann S
Mol Med Rep; 2016 Mar; 13(3):2338-44. PubMed ID: 26782932
[TBL] [Abstract][Full Text] [Related]
4. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
Jedlinski A; Ansell A; Johansson AC; Roberg K
J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
[TBL] [Abstract][Full Text] [Related]
5. Serine mutations that abrogate ligand-induced ubiquitination and internalization of the EGF receptor do not affect c-Cbl association with the receptor.
Oksvold MP; Thien CB; Widerberg J; Chantry A; Huitfeldt HS; Langdon WY
Oncogene; 2003 Nov; 22(52):8509-18. PubMed ID: 14627991
[TBL] [Abstract][Full Text] [Related]
6. Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors.
Kim Y; Apetri M; Luo B; Settleman JE; Anderson KS
Mol Cancer Res; 2015 Apr; 13(4):765-74. PubMed ID: 25573954
[TBL] [Abstract][Full Text] [Related]
7. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
8. Cbl and Itch binding sites in ERBB4 CYT-1 and CYT-2 mediate K48- and K63-polyubiquitination, respectively.
Meijer IM; van Rotterdam W; van Zoelen EJ; van Leeuwen JE
Cell Signal; 2013 Feb; 25(2):470-8. PubMed ID: 23153581
[TBL] [Abstract][Full Text] [Related]
9. Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl.
Hosaka T; Inoue F; Ando K; Ishida H; Kusumoto S; Sugiyama T; Shirai T; Okuda K; Hirose T; Ohnishi T; Horichi N; Saijo N; Adachi M; Nakadate T; Kuroki T; Ohmori T
Anticancer Res; 2007; 27(4B):2253-63. PubMed ID: 17695511
[TBL] [Abstract][Full Text] [Related]
10. Flotillin-2 regulates epidermal growth factor receptor activation, degradation by Cbl-mediated ubiquitination, and cancer growth.
Wisniewski DJ; Liyasova MS; Korrapati S; Zhang X; Ratnayake S; Chen Q; Gilbert SF; Catalano A; Voeller D; Meerzaman D; Guha U; Porat-Shliom N; Annunziata CM; Lipkowitz S
J Biol Chem; 2023 Jan; 299(1):102766. PubMed ID: 36470425
[TBL] [Abstract][Full Text] [Related]
11. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor fate is controlled by Hrs tyrosine phosphorylation sites that regulate Hrs degradation.
Stern KA; Visser Smit GD; Place TL; Winistorfer S; Piper RC; Lill NL
Mol Cell Biol; 2007 Feb; 27(3):888-98. PubMed ID: 17101784
[TBL] [Abstract][Full Text] [Related]
13. Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor.
Timpson P; Lynch DK; Schramek D; Walker F; Daly RJ
Cancer Res; 2005 Apr; 65(8):3273-80. PubMed ID: 15833860
[TBL] [Abstract][Full Text] [Related]
14. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
Secades P; de Santa-María IS; Merlo A; Suarez C; Chiara MD
Head Neck; 2015 Aug; 37(8):1150-62. PubMed ID: 24798801
[TBL] [Abstract][Full Text] [Related]
15. Cbl-family ubiquitin ligases and their recruitment of CIN85 are largely dispensable for epidermal growth factor receptor endocytosis.
Ahmad G; Mohapatra BC; Schulte NA; Nadeau SA; Luan H; Zutshi N; Tom E; Ortega-Cava C; Tu C; Sanada M; Ogawa S; Toews ML; Band V; Band H
Int J Biochem Cell Biol; 2014 Dec; 57():123-34. PubMed ID: 25449262
[TBL] [Abstract][Full Text] [Related]
16. Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers.
Kim KK; Han A; Yano N; Ribeiro JR; Lokich E; Singh RK; Moore RG
Sci Rep; 2015 Nov; 5():15911. PubMed ID: 26568478
[TBL] [Abstract][Full Text] [Related]
17. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation.
Grøvdal LM; Stang E; Sorkin A; Madshus IH
Exp Cell Res; 2004 Nov; 300(2):388-95. PubMed ID: 15475003
[TBL] [Abstract][Full Text] [Related]
18. Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells.
Takaoka S; Iwase M; Uchida M; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M; Shintani S
Int J Oncol; 2007 Jun; 30(6):1469-76. PubMed ID: 17487368
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
20. Prestimulation of head and neck cancer cells with growth factors enhances treatment efficacy.
Hambek M; Werner C; Baghi M; Gstöttner W; Knecht R
Anticancer Res; 2006; 26(2A):1091-5. PubMed ID: 16619511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
